AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics


AcelRx Pharmaceuticals, Inc. (ACRX)

Today's Latest Price: $1.52 USD

0.02 (-1.30%)

Updated Nov 27 1:00pm

Add ACRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACRX Stock Summary

  • ACRX's price/sales ratio is 27.04; that's higher than the P/S ratio of 93.03% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.41 for Acelrx Pharmaceuticals Inc; that's greater than it is for only 5.51% of US stocks.
  • Revenue growth over the past 12 months for Acelrx Pharmaceuticals Inc comes in at 112.32%, a number that bests 95.12% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ACRX, based on their financial statements, market capitalization, and price volatility, are SIBN, IGC, MNKD, XGN, and CDXC.
  • Visit ACRX's SEC page to see the company's official filings. To visit the company's web site, go to www.acelrx.com.

ACRX Stock Price Chart Interactive Chart >

Price chart for ACRX

ACRX Price/Volume Stats

Current price $1.52 52-week high $2.50
Prev. close $1.54 52-week low $0.70
Day low $1.50 Volume 585,044
Day high $1.57 Avg. volume 1,252,462
50-day MA $1.62 Dividend yield N/A
200-day MA $1.37 Market Cap 137.53M

AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.


ACRX Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRX Latest Social Stream


Loading social stream, please wait...

View Full ACRX Social Stream

Latest ACRX News From Around the Web

Below are the latest news stories about Acelrx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACRX as an investment opportunity.

AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA®

REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it will host a…

PR Newswire | September 29, 2020

AcelRx awarded ~$3.6M contract for DSUVIA by U.S. Army

AcelRx Pharmaceuticals ([[ACRX]] +1.9%) has been awarded an initial contract of up to ~$3.6M for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines, by the U.S. Army.This award is in addition to expected purchases from the U.S. Army for the initial stocking...

Seeking Alpha | September 22, 2020

AcelRx Pharmaceuticals, Cardiff Oncology leads healthcare gainers, iCAD, Pieris Pharmaceuticals among major losers

Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biotech (LEGN) -18%, Tenet Healthcare (THC) -15%, Universal Health Services (UHS) -13%....

Seeking Alpha | September 21, 2020

AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the U.S….

PR Newswire | September 14, 2020

AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Orthopedic Patients in the Perioperative Setting

REDWOOD CITY, Calif., Aug. 24, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an…

PR Newswire | August 24, 2020

Read More 'ACRX' Stories Here

ACRX Price Returns

1-mo -14.61%
3-mo 23.58%
6-mo 9.35%
1-year -13.64%
3-year -30.91%
5-year -72.95%
YTD -27.96%
2019 -8.66%
2018 14.07%
2017 -22.12%
2016 -32.47%
2015 -42.79%

Continue Researching ACRX

Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:

Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8467 seconds.